Over a week ago
Recommendations
Nevro (NVRO) and Boston…
Nevro (NVRO) and Boston Scientific (BSX) announced that they have reached a settlement in the ongoing intellectual property litigation regarding spinal cord stimulation technology therapy, which brings a close to the multi-year litigation between the parties, Piper Sandler analyst Adam Maeder tells investors in a research note. The settlement gives Boston Scientific the freedom to operate below 1,500Hz using the features/capabilities in its current product offerings, while Nevro has freedom to operate using the features/capabilities in its current product lines, says the analyst. He believes Nevro has successfully defended its exclusive ability to use high-frequency stimulation and notes it remains the only SCS player able to legally use frequencies above 1,500Hz. Maeder keeps a Neutral rating on the shares with a $64 price target.
Show Hide Related Items >> <<
08/01/22 Nevro, Boston Scientific settle ongoing intellectual property litigations 07/05/22 Nevro announces 12-month results from SENZA-PDN randomized controlled trial 03/07/22 Nevro announces positive Medicare coverage update from Noridian 02/11/22 Nevro's back pain therapy demonstrates effiacy in published 12-month study 06/15/22 Boston Scientific to buy majority stake in M.I.Tech Co. for $230M 03/16/22 Sight Sciences appoints Brenda Becker to board of directors 02/18/22 FTC approves changes to Boston Scientific divestiture agreement 05/26/22 JMP Securities Nevro price target lowered to $95 from $125 at JMP Securities 05/17/22 Citi Nevro price target lowered to $68 from $78 at Citi 05/05/22 Citi Nevro upgraded to Buy from Neutral at Citi 05/05/22 Piper Sandler Nevro price target lowered to $64 from $65 at Piper Sandler 07/28/22 Canaccord Boston Scientific price target raised to $45 from $43 at Canaccord 07/28/22 BTIG Boston Scientific price target raised to $50 from $45 at BTIG 07/27/22 Piper Sandler Piper trims Boston Scientific target, says stock 'a crowded long for a reason' 07/20/22 Truist Boston Scientific price target lowered to $45 from $51 at Truist 02/23/22 Nevro sees 2022 revenue $415M-$430M, consensus $424.28M 02/23/22 Nevro sees Q1 revenue $85M-$87M, consensus $92.6M 02/23/22 Nevro reports Q4 EPS (86c), consensus (86c) 07/27/22 Boston Scientific cuts FY22 adjusted EPS view to $1.74-$1.77 from $1.74-$1.79 07/27/22 Boston Scientific sees Q3 adjusted EPS 43c-45c, consensus 45c 07/27/22 Boston Scientific reports Q2 adjusted EPS 44c, consensus 42c 07/26/22 Notable companies reporting before tomorrow's open 05/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/02/22 What You Missed On Wall Street On Wednesday 03/02/22 What You Missed On Wall Street This Morning 03/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/27/22 Fly Intel: Pre-market Movers 07/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/27/22 Fly Intel: Pre-market Movers 02/02/22 Fly Intel: Pre-market Movers 07/20/22 Boston Scientific put volume heavy and directionally bearish 06/24/22 Boston Scientific call volume above normal and directionally bullish 06/17/22 Boston Scientific call volume above normal and directionally bullish 06/13/22 Boston Scientific call volume above normal and directionally bullish
Hot Stocks
Nevro (NVRO) and Boston…
Nevro (NVRO) and Boston Scientific (BSX) announced that they have reached a settlement in their ongoing intellectual property litigations that gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, and gives Nevro the freedom to operate using the features and capabilities embodied in its current line of products. Nevro will grant Boston Scientific a worldwide, non-exclusive, non-transferable license to practice paresthesia-free therapy at frequencies below 1,500 Hz and a covenant not to sue for any features embodied in any current Boston Scientific products for frequencies below 1,500 Hz. Boston Scientific also will grant Nevro a worldwide, non-exclusive, non-transferable license under Boston Scientific's asserted patent families and a covenant not to sue for any features embodied in any current Nevro products. This settlement concludes all of the existing litigations between Nevro and Boston Scientific, and includes a net payment from Boston Scientific to Nevro of $85M.
Show Hide Related Items >> <<
07/05/22 Nevro announces 12-month results from SENZA-PDN randomized controlled trial 03/07/22 Nevro announces positive Medicare coverage update from Noridian 02/11/22 Nevro's back pain therapy demonstrates effiacy in published 12-month study 06/15/22 Boston Scientific to buy majority stake in M.I.Tech Co. for $230M 03/16/22 Sight Sciences appoints Brenda Becker to board of directors 02/18/22 FTC approves changes to Boston Scientific divestiture agreement 05/26/22 JMP Securities Nevro price target lowered to $95 from $125 at JMP Securities 05/17/22 Citi Nevro price target lowered to $68 from $78 at Citi 05/05/22 Citi Nevro upgraded to Buy from Neutral at Citi 05/05/22 Piper Sandler Nevro price target lowered to $64 from $65 at Piper Sandler 07/28/22 Canaccord Boston Scientific price target raised to $45 from $43 at Canaccord 07/28/22 BTIG Boston Scientific price target raised to $50 from $45 at BTIG 07/27/22 Piper Sandler Piper trims Boston Scientific target, says stock 'a crowded long for a reason' 07/20/22 Truist Boston Scientific price target lowered to $45 from $51 at Truist 02/23/22 Nevro sees 2022 revenue $415M-$430M, consensus $424.28M 02/23/22 Nevro sees Q1 revenue $85M-$87M, consensus $92.6M 02/23/22 Nevro reports Q4 EPS (86c), consensus (86c) 07/27/22 Boston Scientific cuts FY22 adjusted EPS view to $1.74-$1.77 from $1.74-$1.79 07/27/22 Boston Scientific sees Q3 adjusted EPS 43c-45c, consensus 45c 07/27/22 Boston Scientific reports Q2 adjusted EPS 44c, consensus 42c 07/26/22 Notable companies reporting before tomorrow's open 05/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/02/22 What You Missed On Wall Street On Wednesday 03/02/22 What You Missed On Wall Street This Morning 03/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/27/22 Fly Intel: Pre-market Movers 07/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/27/22 Fly Intel: Pre-market Movers 02/02/22 Fly Intel: Pre-market Movers 07/20/22 Boston Scientific put volume heavy and directionally bearish 06/24/22 Boston Scientific call volume above normal and directionally bullish 06/17/22 Boston Scientific call volume above normal and directionally bullish 06/13/22 Boston Scientific call volume above normal and directionally bullish
Recommendations
Canaccord analyst William…
Canaccord analyst William Plovanic raised the firm's price target on Boston Scientific to $45 from $43 and keeps a Buy rating on the shares. The analyst continues to stick to his thesis, that Watchman, Farapulse, and Acurate neo2 will drive future growth for the company.
Show Hide Related Items >> <<
06/15/22 Boston Scientific to buy majority stake in M.I.Tech Co. for $230M 03/16/22 Sight Sciences appoints Brenda Becker to board of directors 02/18/22 FTC approves changes to Boston Scientific divestiture agreement 07/28/22 BTIG Boston Scientific price target raised to $50 from $45 at BTIG 07/27/22 Piper Sandler Piper trims Boston Scientific target, says stock 'a crowded long for a reason' 07/20/22 Truist Boston Scientific price target lowered to $45 from $51 at Truist 07/06/22 Wolfe Research Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform 07/27/22 Boston Scientific cuts FY22 adjusted EPS view to $1.74-$1.77 from $1.74-$1.79 07/27/22 Boston Scientific sees Q3 adjusted EPS 43c-45c, consensus 45c 07/27/22 Boston Scientific reports Q2 adjusted EPS 44c, consensus 42c 07/26/22 Notable companies reporting before tomorrow's open 07/27/22 Fly Intel: Pre-market Movers 07/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/27/22 Fly Intel: Pre-market Movers 02/02/22 Fly Intel: Pre-market Movers 07/20/22 Boston Scientific put volume heavy and directionally bearish 06/24/22 Boston Scientific call volume above normal and directionally bullish 06/17/22 Boston Scientific call volume above normal and directionally bullish 06/13/22 Boston Scientific call volume above normal and directionally bullish
Recommendations
BTIG analyst Marie…
BTIG analyst Marie Thibault raised the firm's price target on Boston Scientific to $50 from $45 and keeps a Buy rating on the shares. The company's Q2 results were "solid" as management also boosted its outlook for organic sales growth, the analyst tells investors in a research note. Thibault further cites Boston Scientific commentary as "more encouraging" than that of other large-cap MedTech peers, with management citing strong global execution during Q2 and calling for an acceleration in the second half of the year despite hospital staffing challenges.
Show Hide Related Items >> <<
06/15/22 Boston Scientific to buy majority stake in M.I.Tech Co. for $230M 03/16/22 Sight Sciences appoints Brenda Becker to board of directors 02/18/22 FTC approves changes to Boston Scientific divestiture agreement 07/27/22 Piper Sandler Piper trims Boston Scientific target, says stock 'a crowded long for a reason' 07/20/22 Truist Boston Scientific price target lowered to $45 from $51 at Truist 07/06/22 Wolfe Research Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform 07/05/22 Wolfe Research Boston Scientific initiated with an Outperform at Wolfe Research 07/27/22 Boston Scientific cuts FY22 adjusted EPS view to $1.74-$1.77 from $1.74-$1.79 07/27/22 Boston Scientific sees Q3 adjusted EPS 43c-45c, consensus 45c 07/27/22 Boston Scientific reports Q2 adjusted EPS 44c, consensus 42c 07/26/22 Notable companies reporting before tomorrow's open 07/27/22 Fly Intel: Pre-market Movers 07/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/27/22 Fly Intel: Pre-market Movers 02/02/22 Fly Intel: Pre-market Movers 07/20/22 Boston Scientific put volume heavy and directionally bearish 06/24/22 Boston Scientific call volume above normal and directionally bullish 06/17/22 Boston Scientific call volume above normal and directionally bullish 06/13/22 Boston Scientific call volume above normal and directionally bullish
Recommendations
Piper Sandler analyst…
Piper Sandler analyst Matt O'Brien lowered the firm's price target on Boston Scientific to $47 from $50 and keeps an Overweight rating on the shares after the company reported Q2 sales and EPS ahead of expectations, raised its yearly organic revenue growth guidance "slightly" and "largely maintained" its EPS outlook. Though he trimmed his target on the shares to reflect next year's earnings and multiple compression in large cap medtech, O'Brien contends that Boston Scientific is "a crowded long for a reason" and calls it his "favorite diversified, large cap name" among his medical technology and devices coverage.
Show Hide Related Items >> <<
06/15/22 Boston Scientific to buy majority stake in M.I.Tech Co. for $230M 03/16/22 Sight Sciences appoints Brenda Becker to board of directors 02/18/22 FTC approves changes to Boston Scientific divestiture agreement 07/20/22 Truist Boston Scientific price target lowered to $45 from $51 at Truist 07/06/22 Wolfe Research Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform 07/05/22 Wolfe Research Boston Scientific initiated with an Outperform at Wolfe Research 07/05/22 Piper Sandler Bottom in med tech shares is 'getting close,' says Piper Sandler 07/27/22 Boston Scientific cuts FY22 adjusted EPS view to $1.74-$1.77 from $1.74-$1.79 07/27/22 Boston Scientific sees Q3 adjusted EPS 43c-45c, consensus 45c 07/27/22 Boston Scientific reports Q2 adjusted EPS 44c, consensus 42c 07/26/22 Notable companies reporting before tomorrow's open 07/27/22 Fly Intel: Pre-market Movers 07/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/27/22 Fly Intel: Pre-market Movers 02/02/22 Fly Intel: Pre-market Movers 07/20/22 Boston Scientific put volume heavy and directionally bearish 06/24/22 Boston Scientific call volume above normal and directionally bullish 06/17/22 Boston Scientific call volume above normal and directionally bullish 06/13/22 Boston Scientific call volume above normal and directionally bullish
On The Fly
Check out this morning's…
Show Hide Related Items >> <<
07/07/22 Tempur Sealy extends employment contract of CEO Scott Thompson 02/22/22 Tempur Sealy falls -16.5% 02/22/22 Tempur Sealy falls -13.0% 02/22/22 Tempur Sealy falls -12.9% 07/25/22 Paladin Cloud receives investment from T-Mobile Ventures 07/13/22 T-Mobile, Deutsche Telekom announces Spoke to use T IoT for safer cycling 06/21/22 Dish and T-Mobile expand network services partnership 06/16/22 T-Mobile to offer free in-flight connectivity on select flights starting June 21 07/27/22 Teva announces 2027 financial targets 07/27/22 Teva says 'on track' to achieving 2023 targets 07/27/22 Teva says revenue in international markets 'in-line with expectations' 07/27/22 Teva announces $4.25B opioid agreement with states, Native American Tribes 06/09/22 Sherwin-Williams to acquire Gross & Perthun GmbH, terms not disclosed 04/26/22 Sherwin-Williams rises 8.1% 02/17/22 Sherwin-Williams names Heidi G. Petz as COO, effective March 1 02/16/22 Sherwin-Williams raises quarterly dividend to 60c from 55c 07/27/22 Shopify sees GMV growth outperforming broader retail market in 2H 07/27/22 Shopify expects to generate adjusted operating loss for 2H 07/27/22 Shopify reports Q2 GMV $46.9B, up 11% over last year 07/26/22 Cathie Wood's ARK Investment bought 1.77M shares of Shopify today 07/27/22 ObsEva to inititate mass dismissal process 07/27/22 ObsEva to apply to Swiss court for moratorium 07/27/22 ObsEva to assess strategic options on pipeline development, worldwide rights 07/27/22 ObsEva terminates license agreement with Kissei, plans corporate restructuring 07/26/22 Microsoft now up nearly 5% to $264 after providing Q1 guidance 07/26/22 Microsoft sees Q1 productivity revenue $15.95B-$16.25B 07/26/22 Microsoft says over 4M people have streamed 'Fortnite' via Cloud Gaming 07/26/22 Microsoft to provide forward-looking guidance on earnings call 07/20/22 Humana to hire 300 seasonal employees 06/13/22 Humana launches CenterWell Pharmacy, CenterWell Specialty Pharmacy 06/09/22 Humana's onehome announces expansion to Virginia 06/07/22 FTC announces inquiry into pharmacy benefit managers $120.40 / -1.775 (-1.45%)
07/27/22 Hilton expects FY22 capital return of $1.5B-$1.9B 07/27/22 Hilton reports Q2 system-wide comparable RevPAR up 54.3% y/y 05/16/22 Pershing Square boosts Canadian Pacific, cuts Domino's in Q1 05/03/22 Hilton seeing 'nice uptick' in return to business transient 07/27/22 Freshworks launches integration with Google's Business Messages 07/26/22 Alphabet Class A expects larger headwind from foreign exchange in Q3 07/26/22 Alphabet Class A shares up 3% to $108.35 after Q2 earnings 07/26/22 Alphabet CFO says 'consistent investments' reflected in 'solid' Q2 performance 07/27/22 General Dynamics says 'solid quarter from earnings perspective' 07/27/22 General Dynamics CEO says 'demand in the quarter was very strong in Aerospace' 07/27/22 General Dynamics reports Q2 cash provided by operating activities of $659M 07/27/22 General Dynamics reports company-wide backlog of $87.6B 07/26/22 F45 Training cuts FY22 adjusted EBITDA view to $25M-$30M from $90M 07/26/22 F45 Training announces CEO transition, cost reduction 05/17/22 F45 Training falls -9.4% 05/16/22 F45 Training reports Q1 SSS up 6% globally, 40% in the U.S. $1,317.61 / -11.955 (-0.90%)
07/26/22 Chipotle jumps 7% to $1,414 after Q2 profit beats estimates 07/26/22 Chipotle reports Q2 in-restaurant sales increased 35.9% 07/26/22 Chipotle expects 235-250 new restaurant openings in 2022 07/26/22 Chipotle sees Q3 comparable restaurant sales growth mid to high single digits 06/15/22 Boston Scientific to buy majority stake in M.I.Tech Co. for $230M 03/16/22 Sight Sciences appoints Brenda Becker to board of directors 02/18/22 FTC approves changes to Boston Scientific divestiture agreement 07/26/22 Evogene's Biomica doses first patient in Phase I clinical trial of BMC128 07/22/22 Bristol-Myers reports positive CHMP opinion for nivolumab/relatlimab combination 07/21/22 Bristol-Myers announces biopharma collaboration with Jack and Jill of America 07/19/22 Bristol-Myers announces extension of Turning Point Therapeutics tender offer 07/27/22 CPI Aerostructures receives $3.2M order from Boeing 07/27/22 Boeing reports Q2 commercial airplane deliveries of 121 vs. 79 a year ago 07/27/22 Boeing increased 737 production to 31 per month 07/27/22 Boeing reports Q2 operating cash flow of $0.1B 02/14/22 ADP elects David Goeckeler to Board of Directors 07/27/22 Cantor Fitzgerald Teva settlement brings uncertainty to Emergent shares, says Cantor Fitzgerald 06/13/22 UBS Teva initiated with a Neutral at UBS 06/13/22 UBS Teva initiated with a Neutral at UBS 05/17/22 BofA Teva upgraded to Neutral at BofA on potential opioid deal upside 07/22/22 Barclays AT&T downgraded to Equal Weight from Overweight at Barclays 07/20/22 Citi T-Mobile price target raised to $160 from $156 at Citi 07/19/22 Deutsche Bank T-Mobile price target raised to $190 from $185 at Deutsche Bank 07/14/22 RBC Capital T-Mobile price target raised to $158 from $152 at RBC Capital 07/18/22 Cowen Cowen believes Aerospace and Defense quarterly results to be mixed 07/15/22 Benchmark Boeing price target lowered to $200 from $250 at Benchmark 07/14/22 RBC Capital Boeing price target lowered to $200 from $220 at RBC Capital 07/13/22 JPMorgan Boeing price target lowered to $188 from $190 at JPMorgan 07/20/22 Wolfe Research ADP price target lowered to $210 from $235 at Wolfe Research 05/02/22 Mizuho ADP price target raised to $250 from $235 at Mizuho 05/02/22 Barclays ADP price target raised to $257 from $238 at Barclays 05/02/22 Citi ADP price target raised to $230 from $212 at Citi 07/20/22 Truist Boston Scientific price target lowered to $45 from $51 at Truist 07/06/22 Wolfe Research Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform 07/05/22 Wolfe Research Boston Scientific initiated with an Outperform at Wolfe Research 07/05/22 Piper Sandler Bottom in med tech shares is 'getting close,' says Piper Sandler $120.40 / -1.775 (-1.45%)
07/11/22 Evercore ISI Hilton assumed at Outperform from In Line at Evercore ISI 06/28/22 Barclays Hilton initiated with an Equal Weight at Barclays 05/04/22 Deutsche Bank Hilton price target raised to $141 from $136 at Deutsche Bank 02/22/22 Wells Fargo Hilton price target raised to $160 from $147 at Wells Fargo $1,317.61 / -11.955 (-0.90%)
07/27/22 BTIG Chipotle price target lowered to $1,825 from $1,975 at BTIG 07/27/22 Cowen Chipotle price target lowered to $1600 from $1830 at Cowen 07/27/22 Deutsche Bank Chipotle price target lowered to $1,503 from $1,505 at Deutsche Bank 07/27/22 Morgan Stanley Chipotle price target raised to $1,808 from $1,768 at Morgan Stanley 07/27/22 Wedbush Microsoft price target lowered to $320 from $340 at Wedbush 07/27/22 Cowen Microsoft price target lowered to $320 from $330 at Cowen 07/27/22 Deutsche Bank Microsoft price target lowered to $330 from $350 at Deutsche Bank 07/27/22 JPMorgan Microsoft price target lowered to $305 from $320 at JPMorgan 07/27/22 Susquehanna Alphabet price target lowered to $150 from $187 at Susquehanna 07/27/22 Evercore ISI Alphabet price target lowered to $140 from $155.50 at Evercore ISI 07/27/22 Jefferies Alphabet price target lowered to $130 from $155 at Jefferies 07/27/22 Wells Fargo Alphabet price target lowered to $160 from $170 at Wells Fargo 07/27/22 Raymond James Alphabet price target lowered to $143 from $159 at Raymond James 07/20/22 Canaccord Canaccord starts Arcellx at Buy, sees 'best-in-class' potential 06/23/22 BMO Capital Nuvalent initiated with an Outperform at BMO Capital 06/06/22 H.C. Wainwright Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright 06/05/22 BofA BofA keeps Buy on Bristol-Myers, raises price target to $80 07/18/22 Wells Fargo Sherwin-Williams price target lowered to $270 from $285 at Wells Fargo 07/14/22 Mizuho Sherwin-Williams price target lowered to $294 from $310 at Mizuho 07/13/22 BofA BofA downgrades Sherwin-Williams to Neutral, sees limited catalysts 07/13/22 BofA Sherwin-Williams downgraded to Neutral from Buy at BofA 04/28/22 Susquehanna General Dynamics price target raised to $285 from $280 at Susquehanna 03/29/22 Jefferies Northrop among biggest beneficiaries of DoD budget request, says Jefferies 03/07/22 Wells Fargo General Dynamics price target raised to $282 from $235 at Wells Fargo 02/04/22 Morgan Stanley Morgan Stanley upgrades General Dynamics to Equal Weight on Gulfstream outlook 07/14/22 Truist Humana price target raised to $550 from $490 at Truist 07/05/22 Stifel Stifel says 'logical to assume' Walgreens could look at 1Life Healthcare 06/16/22 Loop Capital Loop starts Humana at Buy on brand and growing portfolio 06/16/22 Loop Capital Humana initiated with a Buy at Loop Capital 07/26/22 Oppenheimer Shopify assumed with an Outperform at Oppenheimer 07/26/22 Stifel BigCommerce price target lowered to $23 from $35 at Stifel 07/26/22 Citi Shopify price target lowered to $37 from $43.20 at Citi 07/18/22 Wells Fargo Shopify price target lowered to $40 from $55 at Wells Fargo 07/20/22 UBS Tempur Sealy price target lowered to $35 from $45 at UBS 06/01/22 Piper Sandler Tempur Sealy downgraded to Neutral from Overweight at Piper Sandler 04/12/22 Loop Capital Tempur Sealy price target lowered to $28 from $35 at Loop Capital 04/06/22 Raymond James Tempur Sealy price target lowered to $38 from $45 at Raymond James 06/03/22 Cantor Fitzgerald ObsEva initiated with an Overweight at Cantor Fitzgerald 04/26/22 Canaccord ObsEva initiated with a Buy at Canaccord 03/28/22 Aegis ObsEva initiated with a Buy at Aegis 03/28/22 H.C. Wainwright ObsEva price target lowered to $11 from $15 at H.C. Wainwright 07/27/22 Baird Baird downgrades F45 Training to Neutral, slashes target to $2 07/27/22 Baird F45 Training downgraded to Neutral from Outperform at Baird 07/27/22 Macquarie F45 Training downgraded to Neutral from Outperform at Macquarie 06/13/22 Jefferies Jefferies names five top picks in lifestyle and growth platforms 07/27/22 Tempur Sealy cuts FY22 adjusted EPS view to $2.60-$2.80 from $3.20-$3.40 07/27/22 Tempur Sealy reports Q2 adjusted EPS 58c, consensus 60c 07/27/22 T-Mobile raises FY22 core adjusted EBITDA view to $26B-$26.3B from $25.8B-$26.2B 07/27/22 T-Mobile reports Q2 EPS (9c), consensus 28c 07/26/22 Notable companies reporting before tomorrow's open 07/26/22 Teva backs FY22 EPS view of $2.40-$2.60, consensus $2.46 07/26/22 Teva reports Q2 EPS 68c, consensus 57c 05/03/22 Teva backs FY22 adjusted EPS view $2.40-$2.60, consensus $2.51 05/03/22 Teva reports Q1 EPS 55c, consensus 55c 07/27/22 Sherwin-Williams sees Q3 revenue up in low to mid-teens, consensus $5.73B 07/27/22 Sherwin-Williams lowers FY22 adjusted EPS view to $8.50-$8.80 from $9.25-$9.65 07/27/22 Sherwin-Williams reports Q2 adjusted EPS $2.41, consensus $2.78 07/27/22 Shopify reports Q2 adjusted EPS (3c), consensus 3c 05/05/22 Shopify reports Q1 adjusted EPS 20c, consensus 88c 05/17/22 ObsEva reports Q1 EPS (14c), consensus (20c) 03/10/22 ObsEva reports FY21 EPS (78c), one estimate (73c) 07/26/22 Microsoft sees FY23 revenue growth in double digits, consensus $225.98B 07/26/22 Microsoft reports Q4 EPS $2.23, consensus $2.30 06/02/22 Microsoft lowers Q4 EPS view to $2.24-$2.32 from $2.28-$2.35, consensus $2.33 07/27/22 Humana raises FY22 adjusted EPS view to 'approximately $24.75' 07/27/22 Humana reports Q2 adjusted EPS $8.67, consensus $7.67 $120.40 / -1.775 (-1.45%)
07/27/22 Hilton sees Q3 adjusted EPS $1.16-$1.24, consensus $1.16 07/27/22 Hilton raises FY22 adjusted EPS view to $4.21-$4.46 from $3.77-$4.02 07/27/22 Hilton reports Q2 adjusted EPS $1.29, consensus $1.04 07/26/22 Alphabet reports Q2 EPS $1.21, consensus $1.30 04/26/22 Alphabet reports Q1 EPS $24.62, consensus $25.96 07/27/22 General Dynamics reports Q2 EPS $2.75, consensus $2.72 04/27/22 General Dynamics sees Q2 EPS 10c above Q1 level, consensus $2.86 05/16/22 F45 Training sees FY revenue $255M-$275M, consensus $266.49M 05/16/22 F45 Training reports Q1 EPS 3c, consensus 14c 03/14/22 F45 Training sees FY22 revenue $255M-$275M, consensus $264.54M 03/14/22 F45 Training reports Q4 revenue $61.8M, consensus $62.23M $1,317.61 / -11.955 (-0.90%)
07/26/22 Chipotle reports Q2 adjusted EPS $9.30, consensus $9.04 07/26/22 Notable companies reporting after market close 04/26/22 Chipotle reports Q1 adjusted EPS $5.70, consensus $5.64 04/26/22 Notable companies reporting after market close 07/27/22 Boston Scientific cuts FY22 adjusted EPS view to $1.74-$1.77 from $1.74-$1.79 07/27/22 Boston Scientific sees Q3 adjusted EPS 43c-45c, consensus 45c 07/27/22 Boston Scientific reports Q2 adjusted EPS 44c, consensus 42c 07/27/22 Bristol-Myers sees FY22 adjusted EPS $7.44-$7.74, consensus $7.46 07/27/22 Bristol-Myers reports Q2 adjusted EPS $1.93, consensus $1.79 07/27/22 Boeing reports Q2 core EPS (37c), consensus (16c) 04/27/22 Boeing reports Q1 core EPS ($2.75), consensus (12c) 07/27/22 ADP sees FY23 adjusted EPS growth 13%-16%, consensus $7.74 07/27/22 ADP reports Q4 adjusted EPS $1.50, consensus $1.46
Earnings
Consensus $1.76. Cuts…
Consensus $1.76. Cuts FY22 revenue view to up 6%-8% from up 7%-9%, consensus $12.82B. The company said, "The company now estimates net sales growth for the full year 2022, versus the prior year period, to be in a range of approximately 6.5 to 7.5 percent on a reported basis, and approximately 8 to 9 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates EPS on a GAAP basis in a range of $0.69 to $0.76 and estimates adjusted EPS, excluding certain charges (credits), of $1.74 to $1.77."
Show Hide Related Items >> <<
06/15/22 Boston Scientific to buy majority stake in M.I.Tech Co. for $230M 03/16/22 Sight Sciences appoints Brenda Becker to board of directors 02/18/22 FTC approves changes to Boston Scientific divestiture agreement 07/20/22 Truist Boston Scientific price target lowered to $45 from $51 at Truist 07/06/22 Wolfe Research Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform 07/05/22 Wolfe Research Boston Scientific initiated with an Outperform at Wolfe Research 07/05/22 Piper Sandler Bottom in med tech shares is 'getting close,' says Piper Sandler 07/27/22 Boston Scientific sees Q3 adjusted EPS 43c-45c, consensus 45c 07/27/22 Boston Scientific reports Q2 adjusted EPS 44c, consensus 42c 07/26/22 Notable companies reporting before tomorrow's open 07/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/27/22 Fly Intel: Pre-market Movers 02/02/22 Fly Intel: Pre-market Movers 07/20/22 Boston Scientific put volume heavy and directionally bearish 06/24/22 Boston Scientific call volume above normal and directionally bullish 06/17/22 Boston Scientific call volume above normal and directionally bullish 06/13/22 Boston Scientific call volume above normal and directionally bullish
Earnings
Sees Q3 revenue up 6%-8%,…
Sees Q3 revenue up 6%-8%, consensus $3.2B. The company said, "The company estimates net sales growth for the third quarter of 2022, versus the prior year period, to be in a range of approximately 6 to 8 percent on a reported basis, and approximately 8 to 10 percent on an organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.20 to $0.24 and adjusted EPS, excluding certain charges (credits), of $0.43 to $0.45."
Show Hide Related Items >> <<
06/15/22 Boston Scientific to buy majority stake in M.I.Tech Co. for $230M 03/16/22 Sight Sciences appoints Brenda Becker to board of directors 02/18/22 FTC approves changes to Boston Scientific divestiture agreement 07/20/22 Truist Boston Scientific price target lowered to $45 from $51 at Truist 07/06/22 Wolfe Research Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform 07/05/22 Wolfe Research Boston Scientific initiated with an Outperform at Wolfe Research 07/05/22 Piper Sandler Bottom in med tech shares is 'getting close,' says Piper Sandler 07/27/22 Boston Scientific reports Q2 adjusted EPS 44c, consensus 42c 07/26/22 Notable companies reporting before tomorrow's open 04/27/22 Boston Scientific sees FY22 adjusted EPS $1.74-$1.79, consensus $1.77 07/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/27/22 Fly Intel: Pre-market Movers 02/02/22 Fly Intel: Pre-market Movers 07/20/22 Boston Scientific put volume heavy and directionally bearish 06/24/22 Boston Scientific call volume above normal and directionally bullish 06/17/22 Boston Scientific call volume above normal and directionally bullish 06/13/22 Boston Scientific call volume above normal and directionally bullish
Earnings
Reports Q2 revenue…
Reports Q2 revenue $3.24B, consensus $3.22B. "We had another quarter of excellent performance, a testament to the talent of our global team, the sustainability and diversification of our innovative medical technology portfolio and our strong market positions amid continued macroeconomic challenges," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "As we continue to execute our strategy, we have a tremendous opportunity to continue to deliver on our promise to bring life-changing devices and therapies to more patients who need them."
Show Hide Related Items >> <<
06/15/22 Boston Scientific to buy majority stake in M.I.Tech Co. for $230M 03/16/22 Sight Sciences appoints Brenda Becker to board of directors 02/18/22 FTC approves changes to Boston Scientific divestiture agreement 07/20/22 Truist Boston Scientific price target lowered to $45 from $51 at Truist 07/06/22 Wolfe Research Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform 07/05/22 Wolfe Research Boston Scientific initiated with an Outperform at Wolfe Research 07/05/22 Piper Sandler Bottom in med tech shares is 'getting close,' says Piper Sandler 07/26/22 Notable companies reporting before tomorrow's open 04/27/22 Boston Scientific sees FY22 adjusted EPS $1.74-$1.79, consensus $1.77 04/27/22 Boston Scientific sees Q2 adjusted EPS 41c-43c consensus 44c 07/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/27/22 Fly Intel: Pre-market Movers 02/02/22 Fly Intel: Pre-market Movers 07/20/22 Boston Scientific put volume heavy and directionally bearish 06/24/22 Boston Scientific call volume above normal and directionally bullish 06/17/22 Boston Scientific call volume above normal and directionally bullish 06/13/22 Boston Scientific call volume above normal and directionally bullish
Earnings
Notable companies…
Notable companies reporting before tomorrow's open, with earnings consensus, include T-Mobile (TMUS), consensus 28c... Bristol Myers (BMY), consensus $1.82... Boeing (BA), consensus (16c)... ADP (ADP), consensus $1.46... Sherwing-Williams (SHW), consensus $2.78... General Dynamics (GD), consensus $2.72... Humana (HUM), consensus $7.67... Boston Scientific (BSX), consensus 42c... Shopify (SHOP), consensus 3c... Kraft Heinz (KHC), consensus 68c... Hilton (HLT), consensus $1.04... Rockwell Automation (ROK), consensus $2.39... Tempur Sealy (TPX), consensus 60c.
Show Hide Related Items >> <<
07/07/22 Tempur Sealy extends employment contract of CEO Scott Thompson 02/22/22 Tempur Sealy falls -16.5% 02/22/22 Tempur Sealy falls -13.0% 02/22/22 Tempur Sealy falls -12.9% 07/25/22 Paladin Cloud receives investment from T-Mobile Ventures 07/13/22 T-Mobile, Deutsche Telekom announces Spoke to use T IoT for safer cycling 06/21/22 Dish and T-Mobile expand network services partnership 06/16/22 T-Mobile to offer free in-flight connectivity on select flights starting June 21 06/09/22 Sherwin-Williams to acquire Gross & Perthun GmbH, terms not disclosed 04/26/22 Sherwin-Williams rises 8.1% 02/17/22 Sherwin-Williams names Heidi G. Petz as COO, effective March 1 02/16/22 Sherwin-Williams raises quarterly dividend to 60c from 55c 07/26/22 Cathie Wood's ARK Investment bought 1.77M shares of Shopify today 07/26/22 Shopify confirms reduction in workforce, sees about 10% leaving by end of day 07/19/22 YouTube signs partnership agreement with Shopify 07/14/22 Cathie Wood's ARK Investment bought 343K shares of Shopify today 05/23/22 HP Inc. names Ernest Nicolas as chief supply chain officer 05/03/22 Rockwell Automation CEO: It was a tough quarter, below our expectations 05/03/22 Rockwell Automation falls -13.9% 05/03/22 Rockwell Automation board authorizes additional $1B for share repurchases 06/28/22 Kraft Heinz announces 12-year virtual power purchase agreement with Repsol 05/26/22 3G Capital holds 7.9% of Kraft Heinz shares after share distribution 05/18/22 Kraft Heinz CEO sells $11.5M in common stock 05/13/22 CFTC settles enforcement action against Kraft, Mondelez 07/20/22 Humana to hire 300 seasonal employees 06/13/22 Humana launches CenterWell Pharmacy, CenterWell Specialty Pharmacy 06/09/22 Humana's onehome announces expansion to Virginia 06/07/22 FTC announces inquiry into pharmacy benefit managers $120.40 / -1.775 (-1.45%)
05/16/22 Pershing Square boosts Canadian Pacific, cuts Domino's in Q1 05/03/22 Hilton seeing 'nice uptick' in return to business transient 05/03/22 Hilton considers possibility of modestly higher target leverage range in future 05/03/22 Hilton expects to reach 2019 systemwide RevPAR levels during Q3 07/26/22 Allison Transmission to provide transmission for U.S Army's MPF vehicles 07/20/22 General Dynamics Mission Systems awarded $272.9M contract 07/18/22 General Dynamics' GDIT unit awarded Europe-wide IT, enterprise network contract 07/14/22 General Dynamics awarded $272.98M Navy contract 06/15/22 Boston Scientific to buy majority stake in M.I.Tech Co. for $230M 03/16/22 Sight Sciences appoints Brenda Becker to board of directors 02/18/22 FTC approves changes to Boston Scientific divestiture agreement 07/26/22 Evogene's Biomica doses first patient in Phase I clinical trial of BMC128 07/22/22 Bristol-Myers reports positive CHMP opinion for nivolumab/relatlimab combination 07/21/22 Bristol-Myers announces biopharma collaboration with Jack and Jill of America 07/19/22 Bristol-Myers announces extension of Turning Point Therapeutics tender offer 07/25/22 Boeing forecasts demand for 2.1M new commercial aviation personnel 07/21/22 American Airlines says total debt reduction 'remains a top priority' 07/21/22 Boeing, Cargolux announce 777-8 Freighter as replacement for 747-400 fleet 07/21/22 Boeing, Qatar Airways finalize order for 25 737 Max airplanes 02/14/22 ADP elects David Goeckeler to Board of Directors 07/22/22 Barclays AT&T downgraded to Equal Weight from Overweight at Barclays 07/20/22 Citi T-Mobile price target raised to $160 from $156 at Citi 07/19/22 Deutsche Bank T-Mobile price target raised to $190 from $185 at Deutsche Bank 07/14/22 RBC Capital T-Mobile price target raised to $158 from $152 at RBC Capital 07/20/22 Canaccord Canaccord starts Arcellx at Buy, sees 'best-in-class' potential 06/23/22 BMO Capital Nuvalent initiated with an Outperform at BMO Capital 06/06/22 H.C. Wainwright Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright 06/05/22 BofA BofA keeps Buy on Bristol-Myers, raises price target to $80 07/18/22 Cowen Cowen believes Aerospace and Defense quarterly results to be mixed 07/15/22 Benchmark Boeing price target lowered to $200 from $250 at Benchmark 07/14/22 RBC Capital Boeing price target lowered to $200 from $220 at RBC Capital 07/13/22 JPMorgan Boeing price target lowered to $188 from $190 at JPMorgan 07/20/22 Wolfe Research ADP price target lowered to $210 from $235 at Wolfe Research 05/02/22 Mizuho ADP price target raised to $250 from $235 at Mizuho 05/02/22 Barclays ADP price target raised to $257 from $238 at Barclays 05/02/22 Citi ADP price target raised to $230 from $212 at Citi 07/18/22 Wells Fargo Sherwin-Williams price target lowered to $270 from $285 at Wells Fargo 07/14/22 Mizuho Sherwin-Williams price target lowered to $294 from $310 at Mizuho 07/13/22 BofA BofA downgrades Sherwin-Williams to Neutral, sees limited catalysts 07/13/22 BofA Sherwin-Williams downgraded to Neutral from Buy at BofA 04/28/22 Susquehanna General Dynamics price target raised to $285 from $280 at Susquehanna 03/29/22 Jefferies Northrop among biggest beneficiaries of DoD budget request, says Jefferies 03/07/22 Wells Fargo General Dynamics price target raised to $282 from $235 at Wells Fargo 02/04/22 Morgan Stanley Morgan Stanley upgrades General Dynamics to Equal Weight on Gulfstream outlook 07/14/22 Truist Humana price target raised to $550 from $490 at Truist 07/05/22 Stifel Stifel says 'logical to assume' Walgreens could look at 1Life Healthcare 06/16/22 Loop Capital Loop starts Humana at Buy on brand and growing portfolio 06/16/22 Loop Capital Humana initiated with a Buy at Loop Capital 07/20/22 Truist Boston Scientific price target lowered to $45 from $51 at Truist 07/06/22 Wolfe Research Wolfe Research starts 'Goldilocks stock' Boston Scientific at Outperform 07/05/22 Wolfe Research Boston Scientific initiated with an Outperform at Wolfe Research 07/05/22 Piper Sandler Bottom in med tech shares is 'getting close,' says Piper Sandler 07/26/22 Oppenheimer Shopify assumed with an Outperform at Oppenheimer 07/26/22 Stifel BigCommerce price target lowered to $23 from $35 at Stifel 07/26/22 Citi Shopify price target lowered to $37 from $43.20 at Citi 07/18/22 Wells Fargo Shopify price target lowered to $40 from $55 at Wells Fargo 07/26/22 Morgan Stanley Walmart warning reinforces cautious view of packaged food, says Morgan Stanley 07/18/22 Deutsche Bank Kraft Heinz price target lowered to $47 from $48 at Deutsche Bank 07/18/22 Mizuho Kraft Heinz initiated with a Buy at Mizuho 06/22/22 BMO Capital Kraft Heinz upgraded to Outperform from Market Perform at BMO Capital $120.40 / -1.775 (-1.45%)
07/11/22 Evercore ISI Hilton assumed at Outperform from In Line at Evercore ISI 06/28/22 Barclays Hilton initiated with an Equal Weight at Barclays 05/04/22 Deutsche Bank Hilton price target raised to $141 from $136 at Deutsche Bank 02/22/22 Wells Fargo Hilton price target raised to $160 from $147 at Wells Fargo 07/18/22 Mizuho Rockwell Automation price target lowered to $200 from $215 at Mizuho 07/13/22 Deutsche Bank Rockwell Automation price target lowered to $212 from $250 at Deutsche Bank 07/13/22 Deutsche Bank Rockwell Automation named short-term sell idea at Deutsche Bank 07/12/22 Wells Fargo Rockwell Automation price target lowered to $189 from $190 at Wells Fargo 07/20/22 UBS Tempur Sealy price target lowered to $35 from $45 at UBS 06/01/22 Piper Sandler Tempur Sealy downgraded to Neutral from Overweight at Piper Sandler 04/12/22 Loop Capital Tempur Sealy price target lowered to $28 from $35 at Loop Capital 04/06/22 Raymond James Tempur Sealy price target lowered to $38 from $45 at Raymond James 04/28/22 Tempur Sealy cuts FY22 EPS view to $3.20-$3.40 from $3.65-$3.85 04/28/22 Tempur Sealy reports Q1 adjusted EPS 64c, consensus 60c 04/27/22 Notable companies reporting before tomorrow's open 07/26/22 Notable companies reporting before tomorrow's open 04/27/22 T-Mobile reports Q1 EPS 57c, consensus 32c 04/26/22 Notable companies reporting before tomorrow's open 04/26/22 Sherwin-Williams reaffirms FY22 adjusted EPS view $9.25-$9.65, consensus $9.31 04/26/22 Sherwin-Williams reports Q1 adjusted EPS $1.61, consensus $1.55 04/25/22 Notable companies reporting before tomorrow's open 05/05/22 Shopify reports Q1 adjusted EPS 20c, consensus 88c 05/04/22 Notable companies reporting before tomorrow's open 05/03/22 Rockwell cuts FY22 revenue growth view to 11% - 15% from 16% - 19% 05/03/22 Rockwell Automation cuts FY22 EPS view to $9.20 - $9.80 from $10.50 - $11.10 05/03/22 Rockwell Automation reports Q2 EPS $1.66, consensus $2.26 04/27/22 Kraft Heinz reports Q1 EPS 60c, consensus 53c 06/01/22 Humana backs FY22 adjusted EPS view of about $24.50, consensus $24.63 04/27/22 Humana raises FY22 adjusted EPS view to 'approximately $24.50' 04/27/22 Humana reports Q1 adjusted EPS $8.04, consensus $6.78 $120.40 / -1.775 (-1.45%)
05/03/22 Hilton sees Q2 adjusted EPS 98c-$1.03, consensus $1.07 05/03/22 Hilton sees FY22 adjusted EPS $3.77-$4.02, consensus $4.10 05/03/22 Hilton reports Q1 adjusted EPS 71c, consensus 65c 04/27/22 General Dynamics sees Q2 EPS 10c above Q1 level, consensus $2.86 04/27/22 General Dynamics reports Q1 EPS $2.61, consensus $2.51 04/27/22 Boston Scientific sees FY22 adjusted EPS $1.74-$1.79, consensus $1.77 04/27/22 Boston Scientific sees Q2 adjusted EPS 41c-43c consensus 44c 04/27/22 Boston Scientific reports Q1 adjusted EPS 39c, consensus 39c 04/29/22 Bristol-Myers lowers FY22 adjusted EPS view to $7.44-$7.74 from $7.65-$7.95 04/29/22 Bristol-Myers reports Q1 EPS $1.96, consensus $1.91 04/28/22 Notable companies reporting before tomorrow's open 04/27/22 Boeing reports Q1 core EPS ($2.75), consensus (12c) 04/27/22 ADP raises FY22 adjusted EPS growth view to 15%-17% from 12%-14% 04/27/22 ADP reports Q3 adjusted EPS $2.21, consensus $2.08
